Adakveo (crizanlizumab-tmca) is commonly used to help reduce the frequency of pain crises in people with sickle cell disease.

Adakveo may also be used for other conditions as determined by your health care provider.

​

People with sickle cell disease have red blood cells that are shaped like a sickle. These red blood cells can stick together and block blood flow in different parts of the body, causing serious health problems such as a pain crisis. 

​

Adakveo works by blocking a protein called P-selectin, which plays a role in blood cell stickiness. By blocking this protein, Adakveo helps prevent blood cells from sticking together, which reduces the frequency of pain crises in people with sickle cell disease.